Abstract
Importance Several parameters driving the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain unclear, including age-specific differences in infectivity and susceptibility, and the contribution of inapparent infections to transmission. Robust estimates of key time-to-event distributions remain scarce as well.
Objective Illustrate SARS-CoV-2 transmission patterns and risk factors, and estimate key time-to-event distributions.
Design, Setting, and Participants Individual-based data on 1,178 SARS-CoV-2 infected individuals and their 15,648 contacts identified by contact tracing monitoring over the period from January 13-April 02, 2020 were extracted from the notifiable infectious diseases reporting system in Hunan Province, China. Demographic characteristics, severity classification, exposure and travel history, and key clinical timelines were retrieved.
Exposures Confirmed SARS-CoV-2 infection by positive polymerase chain reaction test result of respiratory samples, and exposure to SARS-CoV-2 infected individuals via household, relative, social, and other types of contacts.
Main Outcomes and Measures The relative contribution of pre-symptomatic and asymptomatic transmission, key time-to-event parameters, and the effect of biological, demographic, and behavioral factors on SARS-CoV-2 infectivity and susceptibility were quantified.
Results Among SARS-CoV-2 infected individuals, the estimated mean serial interval was 5.5 days (95%CI −5.0, 19.9) and the mean generation time was 5.5 days (95%CI 1.7, 11.6). Infectiousness was estimated to peak 1.8 days before symptom onset, with 95% of transmission events occurring between −7.6 days and 7.3 days from the date of symptom onset. The proportion of pre-symptomatic transmission was estimated at 62.5%, while a lower bound for the proportion of asymptomatic transmission was 3.5%. Infectiousness of SARS-CoV-2 was not significantly different between working-age adults (15-59 years old) and other age groups (0-14 years old: p-value=0.16; 60 years and over: p-value=0.33), whilst susceptibility to SARS-CoV-2 infection was estimated to increase with age (p-value=0.03). In addition, transmission risk was higher for household contacts (p-value<0.001), but decreased in later generations of a cluster (second generation: OR=0.13, p-value<0.001; generations 3-4: OR=0.05, p-value<0.001, relative to generation 1) and for those exposed to infectors with a larger number of contacts (p-value=0.04).
Conclusions and Relevance These findings support the contribution of children to transmission and the importance of pre-symptomatic transmission, in turn highlighting the importance of large-scale testing, contact tracing activities, and the use of personnel protective equipment during the COVID-19 pandemic.
Question What are the age-specific differences in infectivity and susceptibility to SARS-CoV-2? What is the role of asymptomatic and pre-symptomatic transmission in the COVID-19 pandemic? What are the risk factors associated with SARS-CoV-2 transmission?
Findings Infectiousness does not differ by age, while susceptibility to SARS-CoV-2 infection increases with age. Up to 62.5% of transmission events may occur before symptom onset and at least 3.5% of transmission events may be linked to asymptomatic shedding. Contacts in the household and exposure to primary cases increase the risk of transmission, while transmission decreases with increasing contacts.
Meaning Our findings support the contribution of children to transmission, and highlight the importance of pre-symptomatic transmission; containment measures should be adjusted accordingly.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2017ZX10103009-005, No. 2018ZX10713001-007, No. 2018ZX10201001-010), and Hunan Provincial Innovative Construction Special Fund: Emergency response to COVID-19 outbreak (No. 2020SK3012).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Institutional review board from Hunan Provincial Center for Disease Control and Prevention (IRB#2020005). Data were deidentified, and informed consent was waived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual-based data on 1,178 SARS-CoV-2 infected individuals and their 15,648 contacts identified by contact tracing monitoring over the period from January 13-April 02, 2020 were extracted from the notifiable infectious diseases reporting system in Hunan Province, China. Demographic characteristics, severity classification, exposure and travel history, and key clinical timelines were retrieved.
